

## Special Issue

# Advances in Squamous Cell Carcinoma: From Pathogenesis to Treatment

### Message from the Guest Editor

Squamous cell carcinoma (SCC) encompasses a diverse group arising from squamous epithelial cells, affecting various anatomical sites such as the skin, head and neck, esophagus, lung, and cervix. Despite sharing histological features, SCCs exhibit significant heterogeneity in their molecular profiles, clinical behavior, and response to therapy. Recent advancements in molecular biology, immunotherapy, and targeted treatments have enhanced our understanding of SCC pathogenesis and opened new avenues for personalized medicine. However, challenges remain in early detection, prognostic assessment, and overcoming therapeutic resistance. This Special Issue aims to collate cutting-edge research and comprehensive reviews that shed light on the molecular mechanisms driving SCC development and progression, novel diagnostic and prognostic biomarkers, and emerging therapeutic strategies. We welcome contributions that explore translational research bridging laboratory findings to clinical applications, as well as studies addressing disparities in SCC outcomes across different populations.

### Guest Editor

Carolin Götz

Chair (Interim) of the Department of Oral and Maxillofacial Surgery,  
Medical University Innsbruck, Innsbruck, Austria

### Deadline for manuscript submissions

20 June 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/243440](https://mdpi.com/si/243440)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)